)
Visual
test
Roivant Sciences
Roivant Sciences (ROIV) investor relations material
Roivant Sciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary6 Feb, 2026
Executive summary
Positive Phase 2 results for brepocitinib in cutaneous sarcoidosis demonstrated strong efficacy and safety, with 100% of high-dose patients achieving clinically meaningful improvement and rapid, deep, sustained benefit in a disease with no approved therapies.
NDA for brepocitinib in dermatomyositis submitted; multiple pivotal and late-stage studies fully enrolled or progressing, including for IMVT-1402 in D2T-RA and mosliciguat in PH-ILD.
$550M Immunovant financing completed, extending cash runway to anticipated commercial launch of Graves' disease therapy.
Consolidated cash, cash equivalents, restricted cash, and marketable securities totaled $4.5 billion as of December 31, 2025, supporting a runway into profitability.
Report covers the quarter ended December 31, 2025, with a focus on biopharmaceutical R&D, pipeline progress, and significant clinical and regulatory milestones.
Financial highlights
R&D expenses for the quarter were $165.4M (GAAP), with non-GAAP at $146.7M–$147M; G&A expenses were $175.1M (GAAP), with non-GAAP at $71M.
Net loss from continuing operations was $313.7M–$314M for the quarter, with non-GAAP net loss at $167M.
Revenue for the quarter was $2.0M, down from $9.0M year-over-year, primarily from license agreements.
Cash, cash equivalents, and marketable securities totaled $4.5B as of December 31, 2025, with no debt.
G&A expenses increased due to a $17.1M impairment loss from HQ relocation and higher share-based compensation.
Outlook and guidance
Multiple pivotal study readouts and regulatory catalysts expected in 2026 and beyond, including Phase 3 for brepocitinib in cutaneous sarcoidosis and non-infectious uveitis, and topline data for IMVT-1402 and mosliciguat.
Anticipated NDA filings and potential commercial launches across 7+ indications by end of 2028.
Management expects existing liquidity to fund operations and capital expenditures for the foreseeable future.
Commercial launches for brepocitinib in dermatomyositis and other indications targeted in the coming years.
Jury trial against Moderna scheduled for March 2026.
How does CS data impact brepocitinib's indication prioritization?
How will IMVT-1402 differentiate in FcRn market?
Mosliciguat PH-ILD commercialization strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and robust acquisitions. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
- 6 FebCRINet loss deepened on lower sales and higher costs, but major new contracts and restructuring are underway.
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRIRevenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects.
- 6 FebNVDA
AI-driven digital twins and real-time simulation will transform engineering and manufacturing. - 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position. - 6 FebCPT
2025 results beat guidance; Sun Belt focus, asset sales, and share buybacks drive 2026 strategy. - 6 FebCRIH1 2025 saw a return to profit, record revenues, and strong cash from major space projects.
Next Roivant Sciences earnings date
TD Cowen 46th Annual Health Care Conference3 Mar, 2026
Roivant Sciences
Next Roivant Sciences earnings date
TD Cowen 46th Annual Health Care Conference3 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company established in 2014, dedicated to the development and commercialization of innovative medicines and technologies, particularly in the areas of inflammation and immunology. The company adopts a unique model, creating nimble and focused subsidiaries known as "Vants" for the development and commercialization of its medicines and technologies. This model has enabled Roivant to bring to market treatments like VTAMA® (tapinarof cream, 1%) for plaque psoriasis in adults, and to advance a diverse pipeline of investigational drugs across its family of companies, including fully human monoclonal antibodies and treatments for autoimmune diseases. Roivant Sciences is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage